The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I. ##STR00001##

 
Web www.patentalert.com

< Venlafaxine formulations and methods of preparing the same

< 3-.beta.-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof

> Quinazolinone T-type calcium channel antagonists

> Processes for preparing venlafaxine and venlafaxine hydrochloride of form I

~ 00621